T ransbronchial needle aspiration (TBNA) is a relatively sensitive, accurate, and safe technique in the diagnosis and staging of lung neoplasms. TBNA includes TBNA, transtracheal needle aspiration, and endobronchial needle aspiration. Major indications for TBNA include diagnosis of mediastinal or hilar adenopathy, extrinsic compression of the airway by a peribronchial process, submucosal disease, and peripheral nodule. 1 Available studies [2] [3] [4] [5] have shown a high yield for diagnostic material, especially, in malignant mediastinal and hilar lesions. Despite ease of use, low complication rate, and a relatively high yield, multiple surveys 6, 7 have shown underutilization of this procedure. In a recent survey study 7 from the United Kingdom, only 27% of responders had performed TBNA sampling over the previous 12 months. In a similar study 6 from the United States, only 11% of respondents (practicing pulmonologists) reported performing TBNA routinely (Ն 85% of cases). Similarly, in a survey from the American College of Chest Physicians Fellow's Conference, only 10% of the in-training participants reported performing TBNA routinely. Thirty percent of respondents stated that they believe TBNA is not useful. However, the majority considered suboptimal bronchoscopy technique and suboptimal cytopathology support as major limitations of TBNA performance. In the same study, 8 most of the participants reported a diagnostic yield of 25% to 80%.
At the Houston Veterans Affairs Medical Center (HVAMC), pulmonary fellows perform bronchoscopic procedures with direct supervision by a pulmonary faculty. Mediastinal masses are the leading reason for referral to our pulmonary section. TBNA is performed on any patient with an accessible mediastinal lesion. To determine our success with this technique, we undertook a retrospective chart review of all TBNAs performed at the HVAMC from January 1991 to July 1999. The purpose of our study was threefold: (1) to determine the diagnostic yield of TBNA when performed by supervised pulmonary fellows, (2) to compare diagnostic yield for different mediastinal pathologies when using TBNA, and (3) to determine the diagnostic yield for mediastinal lesions in different nodal stations (paratracheal vs subcarinal).
Materials and Methods
We reviewed all the bronchoscopies performed at the HVAMC from January 1991 to July 1999. One hundred seventy-three patients who had undergone bronchoscopy with tracheal and/or main carinal fine-needle aspirations (FNAs) were identified. Three patients needed repeat procedures. For statistical analysis, we randomly picked one of the two procedures in these three patients. Therefore, we based our analysis on data available for a total of 170 patients. The final diagnoses were not obtainable in four of the cases.
All of the bronchoscopies with TBNA were performed by supervised pulmonary fellows at the HVAMC. Procedures were performed by 26 Baylor College of Medicine pulmonary fellows and 8 HVAMC staff pulmonologists. A variety of fiberoptic bronchoscopes (models BF IT10 and BF IT 30; Olympus Corporation; Melville, NY) and transbronchial histology (19 gauge) and cytology (21 gauge) needles (BARD-Wang; Billerica, MA) were used for these procedures. All bronchoscopies were performed via the nasal route under local anesthesia and conscious sedation. A cytopathology team composed of a cytotechnologist, a cytopathology fellow or resident, and a staff cytopathologist was present for the procedure. The slides from each pass were stained with a rapid Papanicolaou method and reviewed at the time of the procedure. A preliminary diagnosis was rendered and the bronchoscopy team was notified when adequate material was obtained or when no other procedures were to be performed.
We reviewed medical records of the patients, ascertaining final diagnosis, site of the mediastinal lesions, presence of peripheral and endobronchial lesions, sites of FNAs, and the identities of the operators. Available chest CT scans of these patients (122 patients) were reviewed by one of the authors to determine location, and the maximum and minimum diameters of the mediastinal lesions that underwent FNA. CT scans of subjects who underwent TBNA from 1991 to 1993 were not available at the time of this study because our radiology department does not store the imaging studies Ͼ 4 to 5 years. For classification of the location of each lesion, we used the regional lymph node classification that has previously been described. 9 The mediastinal lesions were classified as follows: (1) right and left paratracheal area (2R and 2L) above a horizontal line drawn tangential to the upper margin of aortic arch and below the upper margin of left brachiocephalic vein; (2) right paratracheal area (4R) between the upper margin of the aortic arch and a line extending across the right main bronchus at the upper margin of the right upper lobe bronchus; (3) left paratracheal area (4L) between the upper margin of the aortic arch and a line extending across the left main bronchus at the upper margin of the left upper lobe bronchus, and medial to ligamentum arteriosum; (4) retrotracheal (3P) nodes; and (5) subcarinal (7) nodes.
The presence of numerous benign lymphocytes, or a clear pathologic tissue diagnosis was considered as an adequate sample. 10 A sample was labeled "adequate or diagnostic" if either a pathologic tissue diagnosis was made with the TBNA or the pathologist reported that numerous benign lymphocytes were present. The TBNA result was considered negative if the sample was reported as "inadequate" or "insufficient."
Results
Of 170 patients, 166 patients had a final diagnosis. One hundred twenty-three patients (72%) had malignancies, 30 patients (18%) had benign disease, and 13 patients (8%) were considered negative for disease. In four patients (2%), a final diagnosis was not available.
One hundred four patients (60%) had an adequate or diagnostic result from TBNA. Eighty-five of 123 patients (69%) with malignancy and 11 of 30 patients (37%) with benign disease (nonnormal) had a diagnostic TBNA (Table 1) . Among primary pulmonary malignancies, 26 of 30 patients (87%) with small cell carcinoma (SCCa) had a positive TBNA, while only 55 of 86 patients (64%) with non-small cell carcinoma (NSCCa) had a positive aspirate (Table 2 ). In benign mediastinal lesions, TBNA yield was higher in patients with sarcoidosis (6 of 11 patients, 63%). Table 3 demonstrates the result for each benign pathologic diagnosis. The differences in diagnostic yield of TBNA between malignant vs benign lesions (Pearson 2 with p ϭ 0.004), and SCCa vs NSCCa were statistically significant (Fisher exact test with p ϭ 0.03).
One hundred thirty-two patients (77%) underwent TBNA of a paratracheal area, and 25 patients (15%) underwent TBNA of the main carina. Subcarinal nodes were reached through the carina, or from the medial wall of the right or left main bronchus. In 13 patients (8%), the exact location of TBNA was not available from the record (paratracheal vs carinal).
Most of the aspirations in our series were performed in the right paratracheal area (61%). The overall yield of TBNA between paratracheal and carinal areas was not different (Pearson 2 with p ϭ 0.79); however, among different paratracheal stations, right paratracheal TBNA had higher yield (Fisher exact test with p ϭ 0.003). Table 4 demonstrates the results of TBNA for each area.
We measured maximum diameter (mean Ϯ SD, 39.8 Ϯ 15.12 mm) and minimum diameter (mean, 28.5 Ϯ 12.20 mm) of the lesions that underwent TBNA in 122 patients with available chest CT scans. Location of the TBNA was specified in 117 of these patients. Table 5 demonstrates TBNA yield stratified according to lesion size. TBNA yield was significantly higher as maximum diameter increased (KruskalWallis test with p ϭ 0.05). Although logistic regression analysis indicated that the presence of malignancy is the major determinant of TBNA yield (p ϭ 0.009), lesion size still contributed after being adjusted for the final diagnosis (one-sided p ϭ 0.04).
We analyzed the data for other factors affecting TBNA yield. There was no significant relationship between presence of diagnostic washing, peripheral mass, endobronchial lesion, or diagnostic transbronchial biopsy with the yield of TBNA. However, TBNA yield was significantly higher in subjects with a positive result from bronchial brushings (Pearson 2 with p ϭ 0.01). TBNA was the only positive test in 58 of the cases (34%). Overall, all bronchoscopic procedures including bronchial brush and wash, BAL, TBNA, and transbronchial biopsy were diagnostic in 127 of patients (75%). The remainder of the cases was diagnosed by mediastinoscopy (n ϭ 18, 11%), biopsy from metastases (n ϭ 7, 4%), transthoracic needle aspiration of lung mass (n ϭ 9, 5%), thoracotomy (n ϭ 1), or autopsy (n ϭ 1). Three of the subjects with nondiagnostic bronchoscopic evaluation were followed up for Ͼ 1 year with no change in size of the mediastinal lymph nodes.
The normal group consisted of subjects with normal lymph node structure (TBNA or mediastinos- copy) or no progression of lymph node size in follow-up for Ͼ 1 year. Of 13 subjects who were considered normal, 8 subjects had a diagnostic normal TBNA (normal lymph node structure). Materials obtained with TBNA were insufficient for diagnosis in 5 of 13 normal subjects. Two of the subjects with nondiagnostic bronchoscopic evaluation underwent mediastinoscopy and had normal lymph node findings by histologic examination. The remaining three subjects had no change in the mediastinal lesions during Ͼ 1 year of follow-up.
Discussion
TBNA is a sensitive, highly specific, minimally invasive technique that has a major role in the diagnosis of mediastinal lesions, and in staging of bronchogenic carcinoma. 11 In our series, all the TBNAs were performed by pulmonary fellows under direct supervision of a staff attending pulmonologists. An overall yield of 60% indicates the usefulness of this diagnostic tool for diagnosis of a variety of mediastinal and hilar lesions even when the operator has limited experience.
The relatively high yield in our center can be attributed in part to the presence of a proper "set-up" for the processing of aspirates. This includes technicians properly trained in the handling of samples, 12 use of CT of the chest in most of the cases prior to the procedures, 5 use of the 19-gauge FNA needle, 3 and the presence of an experienced cytopathologist at the time of procedure (available or requested in the majority of the cases) for rapid on-site evaluation. 13 Our data, and those reported by others, 2, 5 showed that TBNA adds to the diagnostic yield of bronchoscopy. In one third of our patients, TBNA was the only test with a positive diagnostic yield. A positive TBNA usually obviates the need for mediastinoscopy for staging purposes. In our series, 15 of 25 patients with subcarinal lesions had a diagnostic malignant lymph node. None of these patients underwent mediastinoscopy or a futile thoracotomy. Melenka and colleagues 14 reported that using bronchoscopy and TBNA (alone or in combination with chest CT) was consistently the least expensive diagnostic option across a wide range of probabilities, test characteristics, and charges.
TBNA can be used for staging bronchogenic carcinoma with mediastinal or hilar involvement. 2, 4, 15, 16 In our cohort, the most important factor predicting the yield of TBNA was the cell type of the lesion. Multiple studies 5, 17 have shown higher TBNA yield for malignant lesions when compared to benign disease. Among malignant lesions, TBNA yield is higher for SCCa. In another study, 5 the higher TBNA yield for SCCa held true even after adjustment for the size of the lymph nodes. This was attributed to the biological aggressiveness of SCCa, or to lower cellular adherence of these tumor cells.
In this group of patients, we did not find a difference in TBNA diagnostic yield between paratracheal and subcarinal lesions. However, the yield for lesions in the right paratracheal area was higher than for those on the left side. This finding is consistent with that of Harrow et al, 5 who found in a multicenter prospective study that right-sided and subcarinal lesions were more likely to have a diagnostic mediastinal TBNA result. The reason for this difference may in part be due to the presence of large vascular structures in the left paratracheal area. Operators may be less aggressive when performing TBNA of the left paratracheal area because of the supposed risk of puncturing these vascular structures.
Although previous studies 5, 17 have shown significant effect for the size of the mediastinal lesion, our data did show weaker size effect compared to underlying pathology. Harrow et al 5 reported a positive correlation between TBNA yield and increasing lymph node size up to 24 mm. In our study, in 122 patients with a CT scan available allowing lymph node measurement, only 12 patients had lymph nodes with a maximum diameter Ͻ 24 mm. Thus, our sample may not have included a sufficient range of sizes to detect a stronger effect of lymph node dimension on TBNA yield.
Among benign lesions, sarcoidosis has the highest TBNA yield. Our data are in accordance with that of others. Wang et al 18 reported a 90% diagnostic TBNA yield with an 18-gauge needle in 20 patients with sarcoidosis. Positive TBNA in these patients obviated the need for more invasive procedures like mediastinoscopy. TBNA also can be effectively used in diagnosis of other benign mediastinal lesions. In our series, a variety of different pathologies, including tuberculosis, histoplasmosis, thyroid goiter, and reactive lymph nodes, were diagnosed with TBNA.
In the study by Prakash and colleagues, 6 TBNA received the most negative comments. Problems stated by the participants of this survey included damage to the bronchoscope, problems with the needle, unacceptability of the specimens to the pathologist, and lack of training. 6 As stated earlier, Haponik and Shure 8 in a survey from pulmonary fellows found similar comments. In our center, all bronchoscopy procedures are done by the pulmonary fellows under supervision of the staff pulmonologists. Despite the limited experience of our fellows, we did not have any damage to any of the bronchoscopes used for TBNA.
Due to the retrospective nature of these data, our study has limitations. We were not able to confirm the final pathology for the lymph nodes that had negative TBNA results in those patients who did not continue follow-up at our institution (n ϭ 4). In addition, the number of attempts in all of the cases was not clear.
TBNA is indicated for diagnosis of mediastinal or hilar lesions, peribronchial process extrinsically compressing major airway, submucosal disease, peripheral nodule, and in staging of bronchogenic carcinoma. In addition, TBNA has been used for diagnosis of endobronchial lesions, mediastinal cyst, and mediastinal abscess. A major complication of TBNA is damage to the working channel of the fiberoptic bronchoscope. This can be avoided by careful handling of the needle. Complications other than damage to bronchoscope include fever, bacteremia, and minimal bleeding from the puncture site. There is no absolute contraindication for TBNA. Nevertheless, superior vena cava obstruction has been considered as a relative contraindication by some because of potential increased risk of bleeding. Conversely, a retrospective study in 15 patients with superior vena cava obstruction reported negligible bleeding in only 2 patients. 19 In summary, TBNA is a minimally invasive diagnostic technique with high yield, even in the hands of less experienced operators. The yield improves in a proper setting and with experience. Predictors of positive TBNA yield include the underlying diagnosis of malignancy (particularly SCCa), an accessible lesion in the right paratracheal or subcarinal area, and size (Ͼ 24 mm maximum diameter). TBNA in many cases was the only positive diagnostic test. Furthermore, a positive TBNA finding during the staging of lung cancer obviates the need for more invasive diagnostic procedures. This can result in both reductions in morbidity and in significant cost savings.
